PolyPid (PYPD NASDAQ) stock market data APIs
$4.2416
-0.04(-0.9%)
as of February 19, 2026
Try our APIs with
free plan!
PolyPid Financial Data Overview
Price chart is built with
Anychart
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Prev. Close
4.2416
Open
4.203
High
4.2449
Low
4.0907
52 wk Range
2.3-5.12
Market Cap
77 731 K
Shares Outstanding
18 204 K
EPS
-0.41
Beta
1.492
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get PolyPid data using free add-ons & libraries
Get PolyPid Fundamental Data
PolyPid Fundamental data includes:
- Net Revenue:
- EBITDA: -31 345 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-11
- EPS/Forecast: -0.33
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
PolyPid News
New
PolyPid (PYPD) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool. DATE Feb. 11, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Dikla Czaczkes Akselbrad Chief Financial Officer — Jonny Missulawin Chief Operatin...
PolyPid Q4 Earnings Call Highlights
PolyPid logo Key Points FDA-backed rolling NDA path for D-PLEX100: PolyPid received positive FDA feedback supporting a rolling NDA submission for D-PLEX100 with plans to begin by end of Q1 2026, tar...
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
The Company is in AdvancedStagesof Commercial U.S. Partnership Discussions for D-PLEX₁₀₀ Positive FDA Pre-NDA Feedback Supports Rolling NDA Review; Submission Expected to Begin by the End of th...
PolyPid Appoints Brooke Story As Chairman Of Board
(RTTNews) - PolyPid Ltd. (PYPD), a late-stage biopharma company, Tuesday announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025. "Brooke's ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
